Feb. 20, 2020 16:45 UTC The Phase 1/2a trial evaluates a novel route of administration for TG6002, an oncolytic virus that allows the production of chemotherapy agent directly in the tumor STRASBOURG, France--( BUSINESS WIRE )-- Regulatory News: Transgene (Paris:TNG) (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, today announces that the first patient has successfully received TG6002, vi
February 20, 2020
· 7 min read